Abstract: Provided are anti-CD73 antibodies or fragments thereof. The antibodies or fragments therefore include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, a VH CDR3 of SEQ ID NO: 3, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. More generally, antibodies or fragments thereof are described which have specificity to one or more amino acid residues selected from the C-terminal half of a human CD73 protein, such as those in the C-terminal domains. Specific epitope amino acids in these domains include Y345, D399, E400, R401 and R480. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer are also provided.
Type:
Grant
Filed:
February 10, 2020
Date of Patent:
March 28, 2023
Assignee:
I-MAB
Inventors:
Zhengyi Wang, Lei Fang, Bingshi Guo, Jingwu Zang
Abstract: The present invention generally relates to T cell activating bispecific antigen binding molecules, PD-1 axis binding antagonists, and in particular to combination therapies employing such T cell activating bispecific antigen binding molecules and PD-1 axis binding antagonists, and their use of these combination therapies for the treatment of cancer.
Type:
Grant
Filed:
August 7, 2020
Date of Patent:
March 28, 2023
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Christian Klein, Vaios Karanikas, Pablo Umana, Alfred Zippelius, Daniela Stefanie Thommen, Jens Schreiner
Abstract: The present disclosure relates to cell penetrating anti-DNA binding proteins. Compositions comprising these binding proteins may be may be useful for delivering agents to cells and treating diseases such as cancer.
Type:
Grant
Filed:
July 17, 2018
Date of Patent:
March 28, 2023
Assignees:
Nucleus Therapeutics Pty. Ltd, Yale University
Inventors:
James Campbell, Valentina Dubljevic, James Hansen, Zahra Rattray, Jiangbing Zhou
Abstract: The present invention provides a humanized anti-TPBG antibody, a preparation method therefor, a conjugate thereof, and applications. The humanized anti-TPBG antibody comprises: (a), a framework region comprising a residue of a human antibody framework region; and (b) one or more CDRs of a light-chain variable region as shown in the SEQ ID NO:4 or 8 or one or more CDRs of a heavy-chain variable region as shown in the SEQ ID NO:2 or 6.
Abstract: The disclosure provides, inter alia, methods and materials involved in treating cancer using a p53 vaccine in combination with a PD-1 pathway inhibitor.
Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.
Type:
Grant
Filed:
March 23, 2018
Date of Patent:
March 7, 2023
Assignee:
Eisai R&D Management Co., Ltd.
Inventors:
Yasuhiro Funahashi, Tadashi Kadowaki, Junji Matsui, Jason S. Simon, Lucy Xu
Abstract: The disclosure provides a method of immunotherapy for a cancer patient, comprises administering vaccines against Globo series antigens (i.e., Globo H, Stage-specific embryonic antigen 3 “SSEA3” and Stage-specific embryonic antigen 4 “SSEA4”). Specifically, the method comprises administering Globo H-KLH (OBI-822) in patients with Metastatic Breast Cancer. The disclosure also provides a method of comprises selecting a cancer patient who is suitable as treatment candidate for immunotherapy. In addition, the disclosure provides therapeutic agents, including monoclonal antibodies (mAbs) that bind specifically to Globo series antigens and related biomarkers useful in focusing such therapeutic and diagnostic regimens.
Abstract: The present invention relates to an anti-tumor/anti-tumor-associated fibroblast (TAF)/anti-hapten trispecific antibody (TsAb). The anti-hapten domain enables TsAb to arm various hapten-conjugated anti-cancer drugs (nanocarrier drugs, small molecule drugs, protein drugs, and radioactive drugs). The anti-tumor domain enables TsAb-armed drugs to target tumor cells, while the anti-TAF domain enables the TsAb-armed drugs to target TAFs. The present invention allows the simultaneous killing of tumor cells and TAFs by various drugs through arming with TsAb.
Type:
Grant
Filed:
December 11, 2017
Date of Patent:
February 7, 2023
Assignee:
TAIPEI MEDICAL UNIVERSITY
Inventors:
Ming-Thau Sheu, Yuan-Soon Ho, Kuo-Hsiang Chuang, Michael Chen
Abstract: The present disclosure is based on detecting CC chemokine receptor 4 (CCR4) expression on T effector cells to diagnostically or prophylactically predict subjects, in particular those with a gynaecological cancer who will respond to treatment with low dose cyclophosphamide.
Abstract: Described herein are compositions and methods for diagnosing late-onset Alzheimer's disease (LOAD), treating LOAD and assessing efficacy of therapeutic agents used to treat LOAD.
Abstract: This disclosure provides a method for treating a subject afflicted with tumor, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity. In some embodiments, the tumor is derived from a non-small cell lung cancer (NSCLC). In some embodiments, the tumor expresses Programmed Death Ligand 1. In some embodiments, the subject carries a wild-type STK11 gene.
Type:
Grant
Filed:
June 1, 2018
Date of Patent:
January 31, 2023
Assignee:
Bristol-Myers Squibb Company
Inventors:
Robin Edwards, William J. Geese, Danielle M. Greenawalt
Abstract: The present invention discloses a method of treating, preventing or ameliorating tumor growth by administering a therapeutic agent that selectively inhibits dipeptidyl peptidase including fibroblast activation protein and dipeptidyl peptidase 8/9 in combination with an immune checkpoint inhibitor. The method specifically discloses use of Talabostat in combination with an immune checkpoint inhibitor, its pharmaceutical composition and process of preparing such composition.
Abstract: The present invention relates to a method for diagnosis of bile duct cancer, using methionyl-tRNA synthetase (MRS) in bile duct cells of a latent patient.
Type:
Grant
Filed:
November 11, 2019
Date of Patent:
January 24, 2023
Assignee:
ONCOTAG DIAGNOSTICS CO., LTD.
Inventors:
Sunghoon Kim, Nam Hoon Kwon, Dong Ki Lee, Beom Jin Lim, Sung Ill Jang
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Type:
Grant
Filed:
June 17, 2022
Date of Patent:
January 24, 2023
Assignee:
IMMATICS BIOTECHNOLOGIES GMBH
Inventors:
Juliane Sarah Walz, Daniel Johannes Kowalewski, Markus Loeffler, Moreno Di Marco, Nico Trautwein, Annika Nelde, Stefan Stevanovic, Hans-Georg Rammensee, Sebastian Haen
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Type:
Grant
Filed:
July 8, 2022
Date of Patent:
January 24, 2023
Assignee:
IMMATICS BIOTECHNOLOGIES GMBH
Inventors:
Juliane Sarah Walz, Daniel Johannes Kowalewski, Markus Loeffler, Moreno Di Marco, Nico Trautwein, Annika Nelde, Stefan Stevanovic, Hans-Georg Rammensee, Sebastian Haen
Abstract: The present invention provides KOC1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.
Abstract: Gene sequences are tailored for protein expression by measuring ribosome dynamics, training a statistical model of the relationship between DNA sequence and translation speed; and using this model to design an optimal DNA sequence encoding a given protein.
Type:
Grant
Filed:
October 10, 2019
Date of Patent:
December 27, 2022
Assignee:
The Regents of the University of California
Abstract: The present invention relates to anti-CLL-1 antibodies including anti-CLL-1 antibodies comprising a CLL-1 binding domain and a CD3 binding domain (e.g., anti-CLL-1/CD3 T cell dependent bispecific (TDB) antibody) and methods of using the same.
Type:
Grant
Filed:
October 21, 2019
Date of Patent:
October 11, 2022
Assignee:
Genentech, Inc.
Inventors:
Robert F. Kelley, Steven R. Leong, Wei-Ching Liang, Mary Mathieu, Andrew G. Polson, Bing Zheng, Xiaocheng Chen, Cecilia Pui Chi Chiu, Mark S. Dennis, Allen Ebens, Yan Wu
Abstract: Partial depletion of RLIP76 in p53 deficient living subject has shown many health benefits. In one embodiment, partical Rlip depletion is used to prevent or treat cancer in p53 deficient living subjects. In another embodiment, partial Rlip depletion is used for reversion of DNA-methylation abnormalities caused by the lack of p53 to normal in p53 deficient living subjects. In yet another embodiment, partial Rlip depletion is used in reduction of blood glucose, insulin-resistance, hyperlipidemina, or any combination thereof in p53 deficient living subjects. Methods of using liposome containing anti-sense nucleic acid or double stranded siRNA to partially deplete RLIP76 and thus treat p53 deficient subject are disclosed. The approaches described herein can be especially helpful in preventing cancer in Li-Fraumeni patients.
Type:
Grant
Filed:
August 23, 2017
Date of Patent:
August 30, 2022
Assignee:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Abstract: The present invention relates to a set of polypeptides and its uses. In particular, the present invention relates to a set of polypeptides whereby this set comprises two polypeptides each of which comprises a targeting moiety “T” binding to an antigen “?” and a fragment of “F” of a functional domain, wherein said two polypeptides are not associated with each other in absence of a substrate that has “A” at (on) its surface and wherein, upon dimerization of “F”, the resulting dimer becomes functional. Furthermore, medical and diagnostic uses of said set are described. Moreover, the present invention relates to nucleic acid molecule(s) encoding said set of polypeptides. The present invention also relates to a vector comprising the nucleotide sequence of nucleic acid molecule(s) encoding said set of polypeptides. Furthermore, the present invention relates to pharmaceutical compositions comprising said set of polypeptides. Moreover, the present invention relates to a kit comprising said set of polypeptides.